(Q54522260)

English

Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

triple-negative breast cancer

1 reference

based on heuristic

inferred from title

9

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

Drakoulis Yannoukakos

19

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

Irene Konstantopoulou

object named as

Irene Konstantopoulou

20

0 references

Florentia Fostira

1

object named as

Florentia Fostira

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

George Fountzilas

21

object named as

George Fountzilas

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

Dimitrios Pectasides

10

object named as

Dimitrios Pectasides

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

Eleni Timotheadou

5

object named as

Eleni Timotheadou

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

Angelos Koutras

18

object named as

Angelos Koutras

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

Dimitrios Bafaloukos

16

object named as

Dimitrios Bafaloukos

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

Epaminontas Samantas

15

object named as

Epaminontas Samantas

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

George Pentheroudakis

12

object named as

George Pentheroudakis

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

Pavlos Papakostas

11

object named as

Pavlos Papakostas

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

13

object named as

Helen Gogas

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

Evangelos Bournakis

8

object named as

Evangelos Bournakis

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

author name string

Marianthi Tsitlaidou

2

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

Christos Papadimitriou

3

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

Maroulio Pertesi

4

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

Alexandra V Stavropoulou

6

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

Stavros Glentis

7

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

Pantelis Skarlos

14

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

Paris A Kosmidis

17

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

language of work or name

0 references

publication date

21 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

134

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

1

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

353-362

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

Triple negative tumours: a critical review

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Triple-Negative Breast Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

What is triple-negative breast cancer?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Triple-negative breast cancer: risk factors to potential targets

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Triple-negative breast cancer: present challenges and new perspectives

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Molecular stratification of triple-negative breast cancers.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Triple-negative breast cancer: disease entity or title of convenience?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Triple-negative breast cancer: clinical features and patterns of recurrence

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Advances in breast cancer: pathways to personalized medicine

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Higher population-based incidence rates of triple-negative breast cancer among young African-American women : Implications for breast cancer screening recommendations

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Genetic epidemiology of BRCA1.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Characteristics of triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Basal-like breast cancer and the BRCA1 phenotype

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

BRCA1 dysfunction in sporadic basal-like breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Hallmarks of 'BRCAness' in sporadic cancers

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

A simple salting out procedure for extracting DNA from human nucleated cells

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Novel genomic rearrangements in the BRCA1 gene detected in Greek breast/ovarian cancer patients.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Prognostic markers in triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Lack of HIN-1 methylation defines specific breast tumor subtypes including medullary carcinoma of the breast and BRCA1-linked tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Pathology of hereditary breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Triple negative breast cancer: unmet medical needs

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

PARP inhibitors stumble in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

A change in the last base of BRCA1 exon 23, 5586G-->A, results in abnormal RNA splicing

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Haplotype analysis of two recurrent genomic rearrangements in the BRCA1 gene suggests they are founder mutations for the Greek population

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Translating cancer research into targeted therapeutics

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2021-9

21 January 2018

Identifiers

10.1007/S10549-012-2021-9

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/22434525

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54522260&oldid=2212500594"